How to Get Praluent (Alirocumab) in Minnesota

What Is Praluent and Why Minnesota Patients Need It

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits PCSK9, the protein responsible for degrading LDL receptors on liver cells. Blocking PCSK9 allows more receptors to remain active, which pulls more LDL-C out of circulation. For patients in Minnesota whose LDL-C remains dangerously elevated despite maximally tolerated statin therapy and ezetimibe, alirocumab can cut LDL-C by 45 to 60 percent on top of background therapy [1].

The ODYSSEY OUTCOMES trial (N=18,924) is the bedrock evidence for this drug. Published in the New England Journal of Medicine in 2018, the trial randomized patients with recent acute coronary syndrome to alirocumab or placebo on top of high-intensity statin therapy. At a median follow-up of 2.8 years, alirocumab reduced the composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by 15 percent relative to placebo (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001) [1]. The absolute risk reduction was 1.6 percentage points, yielding a number needed to treat of 63 over 2.8 years. Patients whose LDL-C was at or above 100 mg/dL at baseline gained the largest absolute benefit, with a 24 percent relative risk reduction in that subgroup [1].

The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who need additional LDL-C lowering on maximally tolerated statin therapy [2]. A subsequent approval covers homozygous familial hypercholesterolemia in adults and children 13 years and older [2].

Minnesota has an estimated 1 in 250 residents carrying a pathogenic variant for heterozygous FH, consistent with the global prevalence reported by the European Atherosclerosis Society [3]. Many of those individuals go undiagnosed for years. The Dutch Lipid Clinic Network criteria and cascade genetic screening remain the recommended diagnostic frameworks [4].

Who Can Prescribe Praluent in Minnesota

Any Minnesota-licensed prescriber with authority to write Schedule and non-schedule prescription medications can prescribe alirocumab. That includes MDs, DOs, nurse practitioners (NPs) with prescriptive authority under Minnesota Statutes Chapter 148, and physician assistants (PAs) acting within their collaborative agreement [5].

Nurse practitioners in Minnesota have full practice authority as of 2023 under a legislative change that removed the mandatory collaborative practice agreement for experienced NPs [5]. This broadens the pool of telehealth providers who can independently initiate a Praluent prescription without a supervising physician countersigning.

The prescriber does not need to be a cardiologist or lipidologist, though those specialists are most familiar with PA navigation. Primary care physicians and internists write the majority of PCSK9 inhibitor prescriptions nationally, according to IQVIA data cited in the 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction [6].

The ACC 2022 Consensus recommends the following prescribing sequence: confirm maximally tolerated statin therapy, add ezetimibe if LDL-C remains above goal, and then escalate to a PCSK9 inhibitor if LDL-C is still at or above 70 mg/dL for ASCVD patients or at or above 100 mg/dL for primary prevention FH patients [6]. Minnesota prescribers following this stepwise approach will have the documentation payers need to approve a PA.

Telehealth Access to Praluent in Minnesota

Telehealth prescribing of alirocumab is permitted in Minnesota. The Minnesota Board of Medical Practice and the 2020 CARES Act telehealth expansions, subsequently codified in state law, allow a prescriber to establish a valid patient-physician relationship and write non-controlled prescriptions via synchronous audio-video consultation [7].

A valid telehealth encounter for alirocumab requires a real-time, two-way audio and video interaction between prescriber and patient. Audio-only may satisfy requirements for established patients in some clinical contexts, but an initial alirocumab evaluation typically needs video to allow the prescriber to review weight, vital signs, and confirm identity for documentation purposes [7].

HealthRX connects Minnesota patients with board-certified physicians and licensed NPs who specialize in lipid management and cardiovascular risk reduction. After a telehealth visit, the prescriber transmits the prescription electronically to a specialty pharmacy licensed in Minnesota. The pharmacy then handles benefits investigation and prior authorization support, which is where most of the 2 to 6-week timeline is consumed.

Minnesota's telehealth parity law requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services [8]. Medical Assistance (Minnesota's Medicaid program) also covers telemedicine services for enrolled members, meaning cost should not be a barrier to the initial prescriber consultation.

Labs and Workup Required Before a Praluent Prescription in Minnesota

A fasting lipid panel is the minimum workup before initiating alirocumab. Specifically, the prescriber needs a baseline LDL-C, total cholesterol, HDL-C, triglycerides, and non-HDL-C to confirm eligibility and to document treatment failure on prior therapy [6]. Most payers require the lipid panel to be drawn while the patient is on their current statin regimen, not after stopping it, to prove on-treatment LDL-C is still above threshold.

Additional labs that strengthen the clinical case and satisfy many PA forms include:

• A hepatic function panel, because severely elevated transaminases (more than three times the upper limit of normal) are a relative contraindication to statin therapy, which affects the "maximally tolerated statin" requirement [6].
• Creatine kinase if myopathy symptoms are present, to document statin intolerance [9].
• A complete metabolic panel to exclude secondary causes of hypercholesterolemia such as hypothyroidism or nephrotic syndrome [4].
• TSH if hypothyroidism has not been previously excluded as a cause of elevated LDL-C [4].

No renal function monitoring or liver enzyme monitoring is required during alirocumab therapy per the FDA label, unlike statins [2]. The drug is cleared via proteolytic degradation rather than hepatic metabolism, so no dose adjustment is needed for mild to moderate hepatic impairment [2].

Most Minnesota commercial payers and Medical Assistance require documentation of at least one statin trial at the highest tolerated dose, plus ezetimibe 10 mg daily, before approving alirocumab. Some Blue Cross Blue Shield of Minnesota formularies require two statin trials at adequate doses for 90 days each before PA approval is granted. The prescriber should pull pharmacy claims history or request a medication history summary from the patient's dispensing pharmacy to satisfy this requirement efficiently.

Prior Authorization: What Minnesota Payers Require

Prior authorization is mandatory for alirocumab across nearly all commercial insurers and government payers operating in Minnesota. Approval timelines range from 3 business days for expedited urgent requests to 14 business days for standard non-urgent reviews, per Minnesota Statutes Section 62Q.73 governing utilization review [10].

The core elements every Minnesota PA form requests are:

1. Diagnosis code (ICD-10 E78.01 for heterozygous FH, E78.00 for pure hypercholesterolemia, or Z82.49 for family history of cardiovascular disease combined with current ASCVD codes such as I25.10) [11].
2. Current LDL-C value on maximally tolerated statin, with the lab date and the statin name and dose clearly listed.
3. Names, doses, and durations of all prior statin trials and ezetimibe use.
4. Documentation of statin intolerance if applicable, including muscle symptoms and the CK value at time of symptoms.
5. Prescriber NPI, DEA number (not required for alirocumab since it is not controlled, but many forms include the field), and office contact information for peer-to-peer review requests.

Peer-to-peer review calls, where the prescribing physician speaks directly with the payer's medical director, convert denied PA requests to approvals at a significant rate. A 2020 analysis published in JAMA Internal Medicine found that peer-to-peer reviews overturned denials for PCSK9 inhibitors at rates ranging from 50 to 80 percent across major commercial payers [12]. Minnesota patients and prescribers should request a peer-to-peer within 24 hours of receiving an initial denial rather than proceeding directly to a formal appeal.

HealthRX care coordinators assist with PA submission, tracking, and peer-to-peer scheduling as part of the patient onboarding process for alirocumab.

Praluent Pharmacy Options in Minnesota

Alirocumab is a specialty biologic dispensed through specialty pharmacies rather than retail chains, though some retail specialty arms (CVS Specialty, Walgreens Specialty, Optum Rx) can fill it. In Minnesota, the following pharmacy types can legally dispense alirocumab to patients:

• Specialty pharmacies licensed in Minnesota with a physical presence (Accredo, CVS Specialty, Walgreens Specialty, Optum Specialty).
• Out-of-state specialty pharmacies licensed to ship to Minnesota residents, provided they hold a valid non-resident pharmacy permit from the Minnesota Board of Pharmacy [13].
• Mail-order pharmacies operating under the patient's pharmacy benefit manager network.

503A compounding pharmacies cannot legally compound alirocumab or any other biologic monoclonal antibody. Biologics are excluded from 503A compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act because they cannot be adequately characterized as small-molecule drugs [14]. Any provider or clinic offering "compounded alirocumab" is operating outside federal law, and patients should avoid such services.

The prescription is transmitted electronically by the prescriber. The specialty pharmacy then conducts a benefits investigation, which typically takes 1 to 3 business days, and submits the PA on the prescriber's behalf if one is required. Once PA is approved, the pharmacy ships the medication refrigerated (2 to 8 degrees Celsius, which is 36 to 46 degrees Fahrenheit) via overnight or two-day courier to the patient's address in Minnesota [2].

Patients can store alirocumab at room temperature (up to 77 degrees Fahrenheit or 25 degrees Celsius) for up to 30 days once removed from the refrigerator, after which unused pens or prefilled syringes must be discarded [2].

Cost, Insurance Coverage, and Patient Assistance in Minnesota

The list price of Praluent is approximately $5,852 per year for the 75 mg every-two-weeks dosing regimen, based on 2024 Wholesale Acquisition Cost data from Regeneron. After commercial insurance with a typical specialty tier copay, most patients pay between $0 and $150 per month depending on plan design and whether the Praluent Savings Card applies [2].

Minnesota Medical Assistance covers alirocumab for adults with a diagnosis of FH or established ASCVD on maximally tolerated statin therapy, subject to PA. The PA criteria for Minnesota Medical Assistance align broadly with the criteria described above. DHS Minnesota publishes its Preferred Drug List updates quarterly, and alirocumab's PA criteria were last updated in the DHS fee-for-service PDL for fiscal year 2024 [15].

For uninsured or underinsured Minnesota patients, Regeneron and Sanofi offer the Praluent Patient Assistance Program, which provides alirocumab at no cost to patients below 400 percent of the federal poverty level who lack adequate prescription coverage [2]. Patients apply through the manufacturer's website with proof of income and a signed prescriber attestation. Processing typically takes 7 to 10 business days.

The Praluent Savings Card reduces out-of-pocket cost to as low as $0 per month for commercially insured patients who are not enrolled in a government-funded program (Medicare, Medicaid, TRICARE) [2]. Medicare Part D patients may access the Extra Help/Low Income Subsidy program through SSA if their income and assets qualify, which can reduce specialty tier cost-sharing substantially [16].

Transferring an Existing Praluent Prescription to Minnesota

Patients who relocate to Minnesota with an existing alirocumab prescription written in another state can transfer that prescription to a Minnesota specialty pharmacy, provided the prescription was written by a prescriber licensed in the originating state and the prescription is not expired. Most specialty pharmacies treat alirocumab prescriptions as 12-month supplies and will transfer remaining refills to a Minnesota-licensed specialty pharmacy location [13].

The new Minnesota pharmacy will verify the prescription with the originating pharmacy and conduct a fresh benefits investigation under the patient's Minnesota insurance plan. If the patient's insurer changes after the move, a new PA may be required under the new plan's criteria, even if the prior plan had already approved the drug.

Patients who previously received alirocumab under a federal employee health benefit plan or a self-insured employer plan that follows them to Minnesota may not need a new PA if the plan is ERISA-governed and the PA was open-ended rather than tied to a plan year.

Patients should also notify their new Minnesota prescriber of their alirocumab use at their first visit, as the prescriber will need to document ongoing monitoring (LDL-C response at 4 to 12 weeks after initiation or dose change) per ACC and American Heart Association guidelines [17].

Monitoring LDL-C After Starting Praluent

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease recommends checking a fasting lipid panel 4 to 12 weeks after starting or changing the dose of any LDL-C-lowering therapy, including alirocumab [17]. This interval allows confirmation that the drug is working and gives the prescriber documentation of LDL-C response for future PA renewals.

Target LDL-C for patients with established ASCVD on alirocumab is below 70 mg/dL per the 2019 ACC/AHA Cholesterol Guideline, with a very high-risk subgroup target of below 55 mg/dL recommended by the 2022 ACC Expert Consensus [6, 17]. In ODYSSEY OUTCOMES, patients who achieved LDL-C below 25 mg/dL had no increase in adverse events related to very low LDL-C over 2.8 years of follow-up, supporting the safety of aggressive LDL-C lowering with this agent [1].

Once LDL-C is at goal and the PA renewal is established, monitoring can shift to every 3 to 6 months per clinical judgment, or annually for stable patients per AHA guidance [17]. Alirocumab does not require liver enzyme monitoring or CK monitoring in the absence of symptoms, which simplifies long-term follow-up compared to statin management [2].

Minnesota prescribers using HealthRX receive automated lab requisition reminders and can order lipid panels through our in-network lab partners with results routed directly to the prescriber's dashboard, reducing the administrative burden of follow-up monitoring.